Clinical trialNARecruiting
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer
- Outcome
- Ongoing
- Phase
- NA
- Status
- Recruiting
- Study type
- Interventional
- Start
- 21 September 2023
- Expected end
- June 2027
- Enrollment
- 48 participants
- Sites
- 1
- Primary outcomes
- Median Progression Free Survival (PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 12 January 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- BackgroundTumor treating fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells. DOI 10.1080/09553002.2020.1838658↗
- BackgroundAblative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adap… DOI 10.1016/j.adro.2020.06.010↗
- BackgroundUsing adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. DOI 10.1002/cam4.2100↗
- BackgroundTumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results … DOI 10.1016/j.pan.2018.10.004↗
- BackgroundMitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. DOI 10.1016/j.pan.2013.11.009↗